RU2515972C2 - Диазакарбазолы и способы применения - Google Patents

Диазакарбазолы и способы применения Download PDF

Info

Publication number
RU2515972C2
RU2515972C2 RU2010154105/04A RU2010154105A RU2515972C2 RU 2515972 C2 RU2515972 C2 RU 2515972C2 RU 2010154105/04 A RU2010154105/04 A RU 2010154105/04A RU 2010154105 A RU2010154105 A RU 2010154105A RU 2515972 C2 RU2515972 C2 RU 2515972C2
Authority
RU
Russia
Prior art keywords
alkyl
formula
compounds
groups
cancer
Prior art date
Application number
RU2010154105/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2010154105A (ru
Inventor
Хейзел Джоан Дайк
Чарльз ЭЛЛВУД
Эмануэла ГАНСИА
Льюис Дж. ГАЗЗАРД
Саймон Чарльз ГУДЭЙКР
Самуэль С. КИНТЗ
Джозеф П. ЛИССИКАТОС
Калум МАКЛЕОД
Карен Уилльямс
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41066724&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2515972(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2010154105A publication Critical patent/RU2010154105A/ru
Application granted granted Critical
Publication of RU2515972C2 publication Critical patent/RU2515972C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2010154105/04A 2008-06-11 2009-06-10 Диазакарбазолы и способы применения RU2515972C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6074608P 2008-06-11 2008-06-11
US61/060,746 2008-06-11
US14800109P 2009-01-28 2009-01-28
US61/148,001 2009-01-28
PCT/US2009/003492 WO2009151598A1 (en) 2008-06-11 2009-06-10 Diazacarbazoles and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2013156074/04A Division RU2013156074A (ru) 2008-06-11 2013-12-17 Диазакарбазолы и способы применения

Publications (2)

Publication Number Publication Date
RU2010154105A RU2010154105A (ru) 2012-07-20
RU2515972C2 true RU2515972C2 (ru) 2014-05-20

Family

ID=41066724

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2010154105/04A RU2515972C2 (ru) 2008-06-11 2009-06-10 Диазакарбазолы и способы применения
RU2013156074/04A RU2013156074A (ru) 2008-06-11 2013-12-17 Диазакарбазолы и способы применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2013156074/04A RU2013156074A (ru) 2008-06-11 2013-12-17 Диазакарбазолы и способы применения

Country Status (20)

Country Link
US (3) US8501765B2 (https=)
EP (2) EP2706059A1 (https=)
JP (2) JP5599784B2 (https=)
KR (1) KR101710732B1 (https=)
CN (2) CN102119163A (https=)
AR (1) AR072092A1 (https=)
AU (1) AU2009258124C1 (https=)
BR (1) BRPI0909954A2 (https=)
CA (1) CA2725754C (https=)
CL (1) CL2010001415A1 (https=)
DK (1) DK2300475T3 (https=)
ES (1) ES2529361T3 (https=)
IL (1) IL209754A0 (https=)
MX (1) MX2010013627A (https=)
PE (2) PE20140609A1 (https=)
PH (1) PH12013502369A1 (https=)
RU (2) RU2515972C2 (https=)
TW (2) TWI466886B (https=)
WO (1) WO2009151598A1 (https=)
ZA (1) ZA201008483B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
CA2725754C (en) * 2008-06-11 2017-05-23 Hazel Joan Dyke Diazacarbazoles and methods of use
AR072084A1 (es) * 2008-06-12 2010-08-04 Sanofi Aventis Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica como inhibidores de las quinasas pim
BRPI0924844A2 (pt) * 2009-03-24 2016-01-26 Sanofi Sa derivados de azacarbolinas 9h-pirrol[2,3-b:5,4-c']dipiridina, sua preparação e sua utilização terapêutica.
FR2950891B1 (fr) * 2009-10-06 2012-11-09 Sanofi Aventis Derives d'azacarbolines 9h-pyrrolo[2,3-b:5,4-c']dipyridine, leur preparation et leur utilisation therapeutique
US20110183938A1 (en) * 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
ES2621857T3 (es) 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
CN102503959B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
RU2641693C2 (ru) * 2011-11-09 2018-01-22 Кансер Ресёрч Текнолоджи Лимитед Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение
WO2013096687A1 (en) * 2011-12-22 2013-06-27 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
AU2013250726B2 (en) 2012-04-20 2017-01-05 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
EP2671881A1 (en) 2012-06-07 2013-12-11 Syngenta Participations AG. Pesticidally active pyridyl- and pyrimidyl- substituted thiazole derivatives
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
CN107118207B (zh) * 2017-05-22 2020-10-02 苏州东南药业股份有限公司 一类cdk抑制剂的制备方法
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
WO2020061377A1 (en) * 2018-09-19 2020-03-26 Genentech, Inc. Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof
US11485734B2 (en) 2018-10-02 2022-11-01 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C)
CN119350306A (zh) 2018-12-13 2025-01-24 英特维特国际股份有限公司 1-[(3r,4s)-4-氰基四氢吡喃-3-基]-3-[(2-氟-6-甲氧基-4-吡啶基)氨基]吡唑-4-甲酰胺制备方法
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
US12168662B1 (en) 2023-12-15 2024-12-17 King Faisal University Pyrido[4′,3′:4,5]pyrrolo[2,3-c][2,7]naphthyridines compounds as CK2 inhibitors
US12129252B1 (en) 2024-02-15 2024-10-29 King Faisal University Pyrrolo[2,3-c][2,6]naphthyridine-8-carboxylic acids as CK2 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068648A1 (en) * 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
WO2003039545A2 (en) * 2001-11-07 2003-05-15 Millennium Pharmaceuticals, Inc. Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
RU2004103857A (ru) * 2001-07-11 2005-06-20 Фарма Мар, С.А. (Es) Производные вариолина и их применение в качестве противоопухолевых средств

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0300894A3 (en) 2000-03-15 2008-05-28 Sanofi Aventis Deutschland Substituted beta-carbolines, process for their preparation, pharmaceutical compositions containing them and their use
GB0121941D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds
BRPI0407544A (pt) * 2003-02-17 2006-02-14 Pharmacia Italia Spa derivados de pirazol tetracìclicos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas que os compreendem
SE0401655D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
EP1896472A1 (de) * 2005-06-09 2008-03-12 Boehringer Ingelheim International GmbH Alpha-carboline als cdk-1 inhibitoren
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2007313961A1 (en) 2006-10-09 2008-05-08 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2666130A1 (en) 2006-10-09 2008-04-17 Takeda San Diego, Inc. Kinase inhibitors
EP2170886A1 (en) * 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
US8133506B2 (en) 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
WO2009129401A1 (en) 2008-04-16 2009-10-22 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2725754C (en) * 2008-06-11 2017-05-23 Hazel Joan Dyke Diazacarbazoles and methods of use
AR072084A1 (es) * 2008-06-12 2010-08-04 Sanofi Aventis Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica como inhibidores de las quinasas pim
WO2010015589A1 (en) 2008-08-05 2010-02-11 Nycomed Gmbh Benzyl-substituted tetracyclic heterocyclic compounds as pde5 inhibitors
BRPI0924844A2 (pt) * 2009-03-24 2016-01-26 Sanofi Sa derivados de azacarbolinas 9h-pirrol[2,3-b:5,4-c']dipiridina, sua preparação e sua utilização terapêutica.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068648A1 (en) * 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
RU2004103857A (ru) * 2001-07-11 2005-06-20 Фарма Мар, С.А. (Es) Производные вариолина и их применение в качестве противоопухолевых средств
WO2003039545A2 (en) * 2001-11-07 2003-05-15 Millennium Pharmaceuticals, Inc. Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
I.A. BHATTI ET. AL.: "Pyrolysis of 1-substituted pyrazoles and chloroform at 550 DEG C: formation of alpha-carboline form 1-benzylpyrazoles." JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS I, vol. 1997, 1997, pages 3581-3585. R. H. BAHEKAR ET. AL.: "Synthesis of 3,8,9-trisubstituted 1,7,9-triaza-fluorene-6-carboxylic acid derivatives as a new class of insulin secretagogues." BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 15, 2007, pages 5950-5964. *
M. HAYAKAWA ET. AL.: "Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors." BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 17, 2007, pages 2438-2442. *

Also Published As

Publication number Publication date
EP2300475B1 (en) 2014-11-05
PE20110365A1 (es) 2011-07-11
CL2010001415A1 (es) 2011-05-06
AU2009258124A1 (en) 2009-12-17
DK2300475T3 (en) 2014-12-08
MX2010013627A (es) 2010-12-21
CA2725754C (en) 2017-05-23
IL209754A0 (en) 2011-02-28
TW201011023A (en) 2010-03-16
HK1149933A1 (en) 2011-10-21
KR101710732B1 (ko) 2017-02-27
ES2529361T3 (es) 2015-02-19
PE20140609A1 (es) 2014-05-22
AR072092A1 (es) 2010-08-04
EP2706059A1 (en) 2014-03-12
US20150087630A1 (en) 2015-03-26
US20110118230A1 (en) 2011-05-19
EP2300475A1 (en) 2011-03-30
AU2009258124C1 (en) 2016-01-07
CN102119163A (zh) 2011-07-06
AU2009258124B2 (en) 2015-01-29
WO2009151598A1 (en) 2009-12-17
BRPI0909954A2 (pt) 2015-11-03
KR20110015697A (ko) 2011-02-16
ZA201008483B (en) 2012-03-28
PH12013502369A1 (en) 2015-09-21
CA2725754A1 (en) 2009-12-17
US8501765B2 (en) 2013-08-06
RU2010154105A (ru) 2012-07-20
JP5599784B2 (ja) 2014-10-01
CN104059066A (zh) 2014-09-24
US20130261104A1 (en) 2013-10-03
WO2009151598A8 (en) 2010-05-06
TWI466886B (zh) 2015-01-01
TW201512199A (zh) 2015-04-01
AU2009258124A2 (en) 2011-01-20
JP2015028027A (ja) 2015-02-12
JP2011522889A (ja) 2011-08-04
RU2013156074A (ru) 2015-06-27
US9216980B2 (en) 2015-12-22

Similar Documents

Publication Publication Date Title
RU2515972C2 (ru) Диазакарбазолы и способы применения
US9440976B2 (en) 1,7-diazacarbazoles and methods of use
US10065970B2 (en) Tricyclic PI3K inhibitor compounds and methods of use
TW201838981A (zh) 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法
EP2300457B1 (en) Substituted pyrroles and methods of use
HK1195774A (en) Diazacarbazoles and methods of use
HK1149933B (en) Diazacarbazoles and methods of use
HK1174332A (en) 1, 7 - diazacarbazoles and their use in the treatment of cancer

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180611